Adela

Adela Bio's platform captures information from the entire methylome, which enhances the performance of the test and improves treatment decisions. This comprehensive approach increases the chances of detecting cancer signals in the blood, compared to other methods that target a smaller set of genomic regions. The platform also offers enhanced prognostic and predictive abilities, allowing for dynamic monitoring of patients over time.

The company's primary market is healthcare providers and patients who require cancer diagnosis and management. Adela Bio's business model revolves around the development and sale of its genome-wide methylome enrichment platform. The company generates revenue by selling its technology to healthcare providers and laboratories.

Adela Bio is also developing its platform for minimal residual disease (MRD) monitoring, which is a method of detecting the smallest amount of disease left in the body after treatment. This approach is tissue agnostic, meaning it can be used regardless of the type of tissue the cancer originated from. Additionally, the company is working on multi-cancer early detection (MCED), which involves sensitive tumor detection and classification using plasma cell-free DNA methylomes.